What is the clinical evidence from this study?

Study design: Cohort. Population: HIV in pregnancy (n=1513). Intervention: HSV-2 co-infection vs. HSV-2 seronegative. Primary outcome: HIV mother-to-child transmission (MTCT) (AOR 1.43, 95% CI 0.54-3.77, p=0.474).

April 27, 2016BMC Pregnancy and ChildbirthOpen Access

HSV-2 co-infection in HIV-positive pregnant women is not linked to increased mother-to-child transmission.

Q: What does this research mean for the field?

Herpes simplex virus type 2 (HSV-2) co-infection among HIV-positive pregnant women is not associated with an increased risk of HIV mother-to-child transmission. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Why the study?

HSV-2 co-infection may increase HIV mother-to-child transmission risk among HIV-positive women in Ukraine, a setting with high STI prevalence.

Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?

Population

1513 HIV-positive women enrolled in the Ukraine European Collaborative Study from 2007 to 2012

Comparison

HSV-2 seropositive vs HSV-2 seronegative women

Design

Cohort study

Key result

HSV-2 co-infection in HIV-positive pregnant women was not associated with an increased risk of HIV mother-to-child transmission (AOR 1.43, 95% CI 0.54-3.77).

Authors

KAKaroline Aebi‐Popp HBHeather Bailey RMRuslan Malyuta

Discussion

Member takes

Overview

HSV-2 co-infection should not yet influence MTCT risk counseling in HIV pregnancies; leaves open confirmation in larger prospective cohorts.

Study Design

Type

Cohort (n=1,513)

Multicenter

Yes

Structured PICO

Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?

Population

1,513 HIV-positive pregnant women in Ukraine, followed postnatally to evaluate the impact of HSV-2 co-infection on mother-to-child transmission of HIV.

Exposure

HSV-2 seropositivity (co-infection)

Comparator

HSV-2 seronegativity

Outcome

HIV mother-to-child transmission (MTCT)hard clinical

Main Result

Odds Ratio: 1.43 (95% CI 0.54–3.77)

Absolute Event Rate: 2.6% vs 3.2%

p-value: p=0.474

HSV-2 co-infection does not significantly increase the risk of HIV mother-to-child transmission among HIV-positive women receiving high rates of antenatal antiretroviral therapy.

Limitations

Limited statistical power to rule out smaller increases in HIV MTCT risk due to low overall transmission rates.
Unable to adjust for maternal HIV viral load due to limited viral load testing.
Lack of PCR test results and clinical symptom data to determine the timing of HSV-2 seroconversions or prevalence of genital ulcer disease during pregnancy.
Potential selection bias as the postnatal cohort enrolls women retained in HIV care, who may have better uptake of services.

Cite This Study

Aebi‐Popp et al. (2016) conducted a cohort in HIV in pregnancy (n=1,513). HSV-2 co-infection vs. HSV-2 seronegative was evaluated on HIV mother-to-child transmission (MTCT) (AOR 1.43, 95% CI 0.54-3.77, p=0.474). HSV-2 co-infection in HIV-positive pregnant women was not associated with an increased risk of HIV mother-to-child transmission (AOR 1.43, 95% CI 0.54-3.77).

synapsesocial.com/papers/6aacb1c599b6c70902ca0d74 https://doi.org/10.1186/s12884-016-0887-y

View Full Paper

Ask AI

Bookmark

April 27, 2016BMC Pregnancy and ChildbirthOpen Access

HSV-2 co-infection in HIV-positive pregnant women is not linked to increased mother-to-child transmission.

View Full Paper

Ask AI

Bookmark

Why the study?

HSV-2 co-infection may increase HIV mother-to-child transmission risk among HIV-positive women in Ukraine, a setting with high STI prevalence.

Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?

Population

1513 HIV-positive women enrolled in the Ukraine European Collaborative Study from 2007 to 2012

Comparison

HSV-2 seropositive vs HSV-2 seronegative women

Design

Cohort study

Key result

HSV-2 co-infection in HIV-positive pregnant women was not associated with an increased risk of HIV mother-to-child transmission (AOR 1.43, 95% CI 0.54-3.77).

Authors

KAKaroline Aebi‐Popp HBHeather Bailey RMRuslan Malyuta

Discussion

Member takes

Overview

HSV-2 co-infection should not yet influence MTCT risk counseling in HIV pregnancies; leaves open confirmation in larger prospective cohorts.

Study Design

Type

Cohort (n=1,513)

Multicenter

Yes

Structured PICO

Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?

Population

1,513 HIV-positive pregnant women in Ukraine, followed postnatally to evaluate the impact of HSV-2 co-infection on mother-to-child transmission of HIV.

Exposure

HSV-2 seropositivity (co-infection)

Comparator

HSV-2 seronegativity

Outcome

HIV mother-to-child transmission (MTCT)hard clinical

Main Result

Odds Ratio: 1.43 (95% CI 0.54–3.77)

Absolute Event Rate: 2.6% vs 3.2%

p-value: p=0.474

HSV-2 co-infection does not significantly increase the risk of HIV mother-to-child transmission among HIV-positive women receiving high rates of antenatal antiretroviral therapy.

Limitations

Limited statistical power to rule out smaller increases in HIV MTCT risk due to low overall transmission rates.
Unable to adjust for maternal HIV viral load due to limited viral load testing.
Lack of PCR test results and clinical symptom data to determine the timing of HSV-2 seroconversions or prevalence of genital ulcer disease during pregnancy.
Potential selection bias as the postnatal cohort enrolls women retained in HIV care, who may have better uptake of services.

Cite This Study

synapsesocial.com/papers/6aacb1c599b6c70902ca0d74 https://doi.org/10.1186/s12884-016-0887-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark